Joining the cohort in Cambridge, MA, Perceiv AI will receive direct
funding and mentorship from Merck, Northpond Ventures, and McKesson
Ventures to advance its prognostic platform focused on multimodal
data in neurodegenerative diseases.
BOSTON, Jan. 17,
2023 /CNW/ - Perceiv AI announced that the
company has been selected by Merck (NYSE: MRK) for the inaugural
Merck Digital Sciences Studio (MDSS) cohort, along with eight other
early-stage biomedical startups from a pool of 152 applicants. The
program started in November to fuel innovative digital technologies
for drug discovery and development.
"Being selected for the Merck MDSS program is a major
accomplishment for Perceiv AI and a testament to the hard work and
dedication of our team. This partnership is a huge step forward for
us and we are grateful for this opportunity," said CEO and
co-founder Dr. Christian Dansereau.
"We are excited to work alongside such a renowned and respected
company in the healthcare and life sciences industry and to use our
cutting-edge AI technology to make a real impact in the field to
advance pharma R&D innovation for clinical development, patient
identification, clinical trial optimization, and trial
de-risking."
MDSS is a collaboration between Merck and the New Jersey
Innovation Institute, with investments from the Merck Global Health
Innovation Fund, Northpond Ventures, and McKesson Ventures. The
accelerator provides direct investment from Merck, access to
powerful Azure Cloud computing, and technology support provided by
Microsoft for Startups. Additionally, participating companies are
provided opportunities to collaborate with discovery and clinical
scientists at Merck for pilots, where appropriate.
Perceiv AI intends to expand upon its proprietary multimodal
prognostic platform ForesightTM through the
program. The ForesightTM platform, which integrates
longitudinal clinical data with imaging and genetics to forecast
disease progression, supports the development of prognostic
biomarkers for neurological diseases, including Alzheimer's
disease, for clinical trials and clinical use.
Perceiv AI joins Andson Biotech, Deep Forest Sciences,
Gesund.ai, Magna Labs,
IndyGeneUS AI, SciMar ONE, Stem Pharm, and Pepper
Bio in the 10-month accelerator program. The program will
begin with the company's exploration of where its technology can
augment Merck's existing focus areas with the goal of transitioning
into a pilot project with Merck.
This announcement comes on the heels of Perceiv AI's
closing of its financial round at the end of last year. Along
with strategic partners and investors like the one in this program,
Perceiv AI will be able to further develop its
ForesightTM platform.
To learn more about Perceiv AI, please visit www.perceiv.ai.
About Perceiv AI
Perceiv AI is an AI-driven precision medicine company developing
a powerful multimodal prognostic platform to forecast disease
progression in age-related diseases like Alzheimer's. By providing
a window into individual patients' disease progression, Perceiv AI
aims to accelerate and de-risk the development of new therapies
while enabling timelier diagnoses.
About Merck
Merck, also known as MSD outside of the United States and Canada, strives to be the premier
research-intensive biopharmaceutical company through a diverse and
inclusive global workforce. For over 130 years, Merck has been
using the power of leading-edge science to deliver innovative
health solutions to save and improve the health and wellness of
people and animals worldwide with important medicines and
vaccines.
About New Jersey Innovation Institute
New Jersey Innovation Institute (NJII), a 501c3 subsidiary of
NJIT, combines the resources of the university, strong industry and
government relationships, and proven methods to drive innovation
and deliver transformative products and services that make a direct
impact on the economy and the health and welfare of its
participants. To achieve this, NJII is organized into four
divisions that help turn ideas into workable solutions: healthcare,
entrepreneurship, defense and homeland security, and professional
and corporate education. More at njii.com.
About Northpond Ventures
Northpond Ventures is a multi-billion-dollar science-driven
venture capital firm based in Cambridge,
MA; San Francisco, CA; and
Bethesda, MD. Northpond has
consistently been named one of the most active lead life science
investors by both Crunchbase and Silicon Valley Bank. It is deeply
engaged in the academic ecosystem, having founded The Laboratory
for Bioengineering Research and Innovation at Harvard's Wyss Institute; launched the
MIT-Northpond Program - Advancing Life Science & Engineering
Innovation; and sponsored a prize for women entrepreneurs at
MIT. It has led or co-led over 60
financings over the past several years and sits on the board of the
vast majority of these businesses. Learn more at npv.vc.
View original
content:https://www.prnewswire.com/news-releases/merck-selects-perceiv-ai-for-inaugural-digital-sciences-studio-cohort-301724187.html
SOURCE Perceiv AI